Skip to main content
Top
Published in: Nutrition Journal 1/2024

Open Access 01-12-2024 | Type 2 Diabetes | Brief Report

The effect of diet-induced weight loss on circulating homocysteine levels in people with obesity and type 2 diabetes

Authors: Meryem Al Fatly, Monique T. Mulder, Jeanine Roeters van Lennep, Henk J. Blom, Kirsten A.C. Berk

Published in: Nutrition Journal | Issue 1/2024

Login to get access

Abstract

Background/aims

Having type 2 diabetes (T2D) in combination with being overweight results in an additional increase in cardiovascular disease (CVD) risk. In addition, T2D and obesity are associated with increased levels of total homocysteine (tHcy), possibly contributing to the CVD risk. Weight loss dieting has positive effects on several CVD risk factors, but whether it affects tHcy remains unclear. Therefore, the aim of this study was to determine the effect of a calorie restricted diet on tHcy in overweight people with T2D.

Methods

In this post-hoc analysis of the POWER study, adults with T2D and a BMI greater than 27 kg/m² were included from the outpatient diabetes clinic of the Erasmus Medical Center, Rotterdam. The patients were subjected to a very low-calorie diet with fortified meal replacements for 20 weeks. Before and after this intervention, blood samples were collected to measure tHcy and other CVD risk factors like glycaemic and lipid parameters.

Results

161 overweight participants with T2D were included, with a mean age of 54 years (range 26–74), mean weight of 104.6 ± 19.9 kg and mean HbA1c of 62.7 ± 14.3 mmol/mol. At baseline, men displayed higher tHcy than women, and tHcy level was positively correlated with body weight and triglyceride levels, while it was negatively correlated with renal function and HDL cholesterol. During the intervention, bodyweight was reduced by a mean of 9.7% (from 104.6 ± 19.9 to 94.5 ± 18.1 kg p < 0.001), and all measured glycaemic and lipid blood parameters improved significantly. However, tHcy remained unchanged (from 12.1 ± 4.1 to 12.1 ± 4.2 umol/L, p = 0.880). The change in tHcy during the intervention was negatively associated with the change in weight and BMI (p = 0.01 and p = 0.008, respectively). People who lost < 10 kg (n = 92) had a mean tHcy change of -0.47 umol/L, while people who lost more than ≥ 10 kg (n = 69) had a mean tHcy change of 0.60 umol/L (p = 0.021).

Conclusion

In conclusion, our data show that a calorie restricted diet does not affect tHcy in people with T2D and obesity, despite the use of meal replacements fortified with folic acid and vitamin B12. Our data showed a negative correlation between change in tHcy levels and weight loss, suggesting that people who lost more weight (> 10 kg) showed an increase in tHcy. Future studies should explore the potential increase in tHcy induced by weight loss dieting and target the question if tHcy reduction strategies during weight loss could be clinically beneficial.
Literature
1.
go back to reference Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, et al. Risk of cardiovascular and all-cause mortality in individuals with Diabetes Mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, obesity, and Lifestyle Study (AusDiab). Circulation. 2007;116(2):151–7.CrossRefPubMed Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, et al. Risk of cardiovascular and all-cause mortality in individuals with Diabetes Mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, obesity, and Lifestyle Study (AusDiab). Circulation. 2007;116(2):151–7.CrossRefPubMed
2.
go back to reference Piché ME, Tchernof A, Després JP. Obesity phenotypes, Diabetes, and Cardiovascular Diseases. Circ Res. 2020;126(11):1477–500.CrossRefPubMed Piché ME, Tchernof A, Després JP. Obesity phenotypes, Diabetes, and Cardiovascular Diseases. Circ Res. 2020;126(11):1477–500.CrossRefPubMed
3.
go back to reference Grover SA, Kaouache M, Rempel P, Joseph L, Dawes M, Lau DC, et al. Years of life lost and healthy life-years lost from Diabetes and Cardiovascular Disease in overweight and obese people: a modelling study. Lancet Diabetes Endocrinol. 2015;3(2):114–22.CrossRefPubMed Grover SA, Kaouache M, Rempel P, Joseph L, Dawes M, Lau DC, et al. Years of life lost and healthy life-years lost from Diabetes and Cardiovascular Disease in overweight and obese people: a modelling study. Lancet Diabetes Endocrinol. 2015;3(2):114–22.CrossRefPubMed
4.
go back to reference Audelin MC, Genest J. Jr. Homocysteine and Cardiovascular Disease in Diabetes Mellitus. Atherosclerosis. 2001;159(2):497–511.CrossRefPubMed Audelin MC, Genest J. Jr. Homocysteine and Cardiovascular Disease in Diabetes Mellitus. Atherosclerosis. 2001;159(2):497–511.CrossRefPubMed
5.
go back to reference Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8(8):CD006612.PubMed Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8(8):CD006612.PubMed
6.
go back to reference Yuan S, Mason AM, Carter P, Burgess S, Larsson SC. Homocysteine, B vitamins, and Cardiovascular Disease: a mendelian randomization study. BMC Med. 2021;19(1):97.CrossRefPubMedPubMedCentral Yuan S, Mason AM, Carter P, Burgess S, Larsson SC. Homocysteine, B vitamins, and Cardiovascular Disease: a mendelian randomization study. BMC Med. 2021;19(1):97.CrossRefPubMedPubMedCentral
7.
go back to reference Cm P, Homocysteine. Cleveland Clinic; 2023 [updated 2023. Cm P, Homocysteine. Cleveland Clinic; 2023 [updated 2023.
8.
go back to reference Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and Cardiovascular Disease. Annu Rev Med. 1998;49:31–62.CrossRefPubMed Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and Cardiovascular Disease. Annu Rev Med. 1998;49:31–62.CrossRefPubMed
9.
go back to reference Mursleen MT, Riaz S. Implication of homocysteine in Diabetes and impact of folate and vitamin B12 in diabetic population. Diabetes Metab Syndr. 2017;11(Suppl 1):141–S6.CrossRef Mursleen MT, Riaz S. Implication of homocysteine in Diabetes and impact of folate and vitamin B12 in diabetic population. Diabetes Metab Syndr. 2017;11(Suppl 1):141–S6.CrossRef
10.
go back to reference Soedamah-Muthu SS, Chaturvedi N, Teerlink T, Idzior-Walus B, Fuller JH, Stehouwer CD, et al. Plasma homocysteine and microvascular and macrovascular Complications in type 1 Diabetes: a cross-sectional nested case-control study. J Intern Med. 2005;258(5):450–9.CrossRefPubMed Soedamah-Muthu SS, Chaturvedi N, Teerlink T, Idzior-Walus B, Fuller JH, Stehouwer CD, et al. Plasma homocysteine and microvascular and macrovascular Complications in type 1 Diabetes: a cross-sectional nested case-control study. J Intern Med. 2005;258(5):450–9.CrossRefPubMed
11.
go back to reference Lu J, Chen K, Chen W, Liu C, Jiang X, Ma Z, et al. Association of Serum Homocysteine with Cardiovascular and all-cause mortality in adults with Diabetes: a prospective cohort study. Oxid Med Cell Longev. 2022;2022:2156483.CrossRefPubMedPubMedCentral Lu J, Chen K, Chen W, Liu C, Jiang X, Ma Z, et al. Association of Serum Homocysteine with Cardiovascular and all-cause mortality in adults with Diabetes: a prospective cohort study. Oxid Med Cell Longev. 2022;2022:2156483.CrossRefPubMedPubMedCentral
12.
go back to reference Muzurović E, Kraljević I, Solak M, Dragnić S, Mikhailidis DP. Homocysteine and Diabetes: role in macrovascular and microvascular Complications. J Diabetes Complications. 2021;35(3):107834.CrossRefPubMed Muzurović E, Kraljević I, Solak M, Dragnić S, Mikhailidis DP. Homocysteine and Diabetes: role in macrovascular and microvascular Complications. J Diabetes Complications. 2021;35(3):107834.CrossRefPubMed
13.
go back to reference American Diabetes A. 8. Obesity management for the treatment of type 2 Diabetes: standards of Medical Care in Diabetes—2021. Diabetes Care. 2020;44(Supplement1):100–S10. American Diabetes A. 8. Obesity management for the treatment of type 2 Diabetes: standards of Medical Care in Diabetes—2021. Diabetes Care. 2020;44(Supplement1):100–S10.
14.
go back to reference Harder H, Dinesen B, Astrup A. The effect of a rapid weight loss on lipid profile and glycemic control in obese type 2 diabetic patients. Int J Obes Relat Metab Disord. 2004;28(1):180–2.CrossRefPubMed Harder H, Dinesen B, Astrup A. The effect of a rapid weight loss on lipid profile and glycemic control in obese type 2 diabetic patients. Int J Obes Relat Metab Disord. 2004;28(1):180–2.CrossRefPubMed
15.
go back to reference Dhindsa P, Scott AR, Donnelly R. Metabolic and cardiovascular effects of very-low-calorie diet therapy in obese patients with type 2 Diabetes in secondary failure: outcomes after 1 year. Diabet Med. 2003;20(4):319–24.CrossRefPubMed Dhindsa P, Scott AR, Donnelly R. Metabolic and cardiovascular effects of very-low-calorie diet therapy in obese patients with type 2 Diabetes in secondary failure: outcomes after 1 year. Diabet Med. 2003;20(4):319–24.CrossRefPubMed
16.
go back to reference Look ARG, Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term Cardiovascular Disease outcomes in overweight or obese people with type 2 Diabetes: a post-hoc analysis of the look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4(11):913–21.CrossRef Look ARG, Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term Cardiovascular Disease outcomes in overweight or obese people with type 2 Diabetes: a post-hoc analysis of the look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4(11):913–21.CrossRef
17.
go back to reference Global Burden of Metabolic Risk Factors for Chronic, Diseases C, Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, et al. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary Heart Disease and Stroke: a pooled analysis of 97 prospective cohorts with 1·8 million participants. Lancet. 2014;383(9921):970–83.CrossRef Global Burden of Metabolic Risk Factors for Chronic, Diseases C, Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, et al. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary Heart Disease and Stroke: a pooled analysis of 97 prospective cohorts with 1·8 million participants. Lancet. 2014;383(9921):970–83.CrossRef
18.
go back to reference Karatela RA, Sainani GS. Plasma homocysteine in obese, overweight and normal weight hypertensives and normotensives. Indian Heart J. 2009;61(2):156–9.PubMed Karatela RA, Sainani GS. Plasma homocysteine in obese, overweight and normal weight hypertensives and normotensives. Indian Heart J. 2009;61(2):156–9.PubMed
19.
go back to reference Persil-Ozkan O, Yigit E, Yigit Z. Does weight loss affect the parameters that are metabolically related to Cardiovascular Diseases? Saudi Med J. 2019;40(4):347–52.CrossRefPubMedPubMedCentral Persil-Ozkan O, Yigit E, Yigit Z. Does weight loss affect the parameters that are metabolically related to Cardiovascular Diseases? Saudi Med J. 2019;40(4):347–52.CrossRefPubMedPubMedCentral
20.
go back to reference Berk KA, Buijks H, Ozcan B, Van’t Spijker A, Busschbach JJ, Sijbrands EJ. The Prevention of WEight regain in Diabetes type 2 (POWER) study: the effectiveness of adding a combined psychological intervention to a very low calorie diet, design and pilot data of a randomized controlled trial. BMC Public Health. 2012;12:1026.CrossRefPubMedPubMedCentral Berk KA, Buijks H, Ozcan B, Van’t Spijker A, Busschbach JJ, Sijbrands EJ. The Prevention of WEight regain in Diabetes type 2 (POWER) study: the effectiveness of adding a combined psychological intervention to a very low calorie diet, design and pilot data of a randomized controlled trial. BMC Public Health. 2012;12:1026.CrossRefPubMedPubMedCentral
21.
go back to reference Berk KA, Yahya R, Verhoeven AJM, Touw J, Leijten FP, van Rossum EF, et al. Effect of diet-induced weight loss on lipoprotein(a) levels in obese individuals with and without type 2 Diabetes. Diabetologia. 2017;60(6):989–97.CrossRefPubMedPubMedCentral Berk KA, Yahya R, Verhoeven AJM, Touw J, Leijten FP, van Rossum EF, et al. Effect of diet-induced weight loss on lipoprotein(a) levels in obese individuals with and without type 2 Diabetes. Diabetologia. 2017;60(6):989–97.CrossRefPubMedPubMedCentral
22.
go back to reference Sudchada P, Saokaew S, Sridetch S, Incampa S, Jaiyen S, Khaithong W. Effect of folic acid supplementation on plasma total homocysteine levels and glycemic control in patients with type 2 Diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2012;98(1):151–8.CrossRefPubMed Sudchada P, Saokaew S, Sridetch S, Incampa S, Jaiyen S, Khaithong W. Effect of folic acid supplementation on plasma total homocysteine levels and glycemic control in patients with type 2 Diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2012;98(1):151–8.CrossRefPubMed
23.
go back to reference van Oort FV, Melse-Boonstra A, Brouwer IA, Clarke R, West CE, Katan MB, et al. Folic acid and reduction of plasma homocysteine concentrations in older adults: a dose-response study. Am J Clin Nutr. 2003;77(5):1318–23.CrossRefPubMed van Oort FV, Melse-Boonstra A, Brouwer IA, Clarke R, West CE, Katan MB, et al. Folic acid and reduction of plasma homocysteine concentrations in older adults: a dose-response study. Am J Clin Nutr. 2003;77(5):1318–23.CrossRefPubMed
24.
go back to reference Metzner CE, Folberth-Vögele A, Bitterlich N, Lemperle M, Schäfer S, Alteheld B, et al. Effect of a conventional energy-restricted modified diet with or without meal replacement on weight loss and cardiometabolic risk profile in overweight women. Nutr Metab (Lond). 2011;8(1):64.CrossRefPubMed Metzner CE, Folberth-Vögele A, Bitterlich N, Lemperle M, Schäfer S, Alteheld B, et al. Effect of a conventional energy-restricted modified diet with or without meal replacement on weight loss and cardiometabolic risk profile in overweight women. Nutr Metab (Lond). 2011;8(1):64.CrossRefPubMed
26.
go back to reference Tirosh A, Golan R, Harman-Boehm I, Henkin Y, Schwarzfuchs D, Rudich A, et al. Renal function following three distinct weight loss dietary strategies during 2 years of a randomized controlled trial. Diabetes Care. 2013;36(8):2225–32.CrossRefPubMedPubMedCentral Tirosh A, Golan R, Harman-Boehm I, Henkin Y, Schwarzfuchs D, Rudich A, et al. Renal function following three distinct weight loss dietary strategies during 2 years of a randomized controlled trial. Diabetes Care. 2013;36(8):2225–32.CrossRefPubMedPubMedCentral
27.
go back to reference Park SB, Georgiades A. Changes in body composition predict homocysteine changes and hyperhomocysteinemia in Korea. J Korean Med Sci. 2013;28(7):1015–20.CrossRefPubMedPubMedCentral Park SB, Georgiades A. Changes in body composition predict homocysteine changes and hyperhomocysteinemia in Korea. J Korean Med Sci. 2013;28(7):1015–20.CrossRefPubMedPubMedCentral
28.
Metadata
Title
The effect of diet-induced weight loss on circulating homocysteine levels in people with obesity and type 2 diabetes
Authors
Meryem Al Fatly
Monique T. Mulder
Jeanine Roeters van Lennep
Henk J. Blom
Kirsten A.C. Berk
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Nutrition Journal / Issue 1/2024
Electronic ISSN: 1475-2891
DOI
https://doi.org/10.1186/s12937-023-00908-y

Other articles of this Issue 1/2024

Nutrition Journal 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine